Sensus Healthcare
SRTS
About: Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
Employees: 54
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
43% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 14
8% more capital invested
Capital invested by funds: $19M [Q1] → $20.6M (+$1.54M) [Q2]
1.99% more ownership
Funds ownership: 24.41% [Q1] → 26.4% (+1.99%) [Q2]
13% less funds holding
Funds holding: 53 [Q1] → 46 (-7) [Q2]
64% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 11
67% less call options, than puts
Call options by funds: $97K | Put options by funds: $297K
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co.
Yi Chen
|
$8
|
Buy
Maintained
|
12 Aug 2025 |
Lake Street
Ben Haynor
|
$6
|
Buy
Maintained
|
8 Aug 2025 |
Financial journalist opinion
Based on 16 articles about SRTS published over the past 30 days